T-Cell Lymphoma patient recruitment built on one of the largest Lymphoma advocacy networks in clinical research: 80+ partner organizations and direct insight from 1,114 patients.

Leapcure recruits T-Cell Lymphoma patients through 80+ advocacy partnerships and the patient insight that makes studies enroll and retain. We deliver enrollment-ready patients to your sites, and we build community trust in your study ahead of launch.

Talk to our T-Cell Lymphoma teamSee how it works →
891
T-Cell Lymphoma patients engaged
78%
Of engaged PTCL patients interested in trial
60%
Of patients engaged were Peripheral T-Cell Lymphoma
US + EU
Engaged across the US, UK, Spain, and France

Understanding T-Cell Non-Hodgkin Lymphoma as a Clinical Trial Indication

T-cell lymphomas are a group of non-Hodgkin lymphomas that arise from T-cell lymphocytes. They make up a minority of non-Hodgkin lymphoma cases, and peripheral T-cell lymphoma (PTCL) covers several aggressive, biologically distinct subtypes. Because the disease is uncommon and clinically varied, eligible patients are spread thinly across specialist hematology and oncology centers rather than concentrated in any one place.

That makes enrollment hard. Diagnosis depends on specialist pathology, different subtypes qualify for different protocols, and the disease can move quickly, so the window to enroll a patient is often short. Broad digital advertising rarely reaches these patients in time. They learn about research through the advocacy organizations, treatment centers, and communities they already trust, or they do not learn about it at all.

Leapcure recruits T-Cell Lymphoma patients through those trusted channels. In a T-Cell / Non-Hodgkin Lymphoma engagement, Leapcure ran a Lymphoma Patient Insights survey with 1,114 responses, used that insight to make the study more patient-centric, and engaged 891 T-Cell Lymphoma patients across the US and Europe. Sixty percent had peripheral T-cell lymphoma, and 78% of those patients were interested in a clinical trial. The work sped up study startup and improved recruitment and retention through patient-informed study design.

The Challenge

T-Cell Lymphoma recruitment demands more than reach. It demands trusted relationships and patient insight.

A rare, dispersed population needs trusted messengers, not broad ads

T-cell lymphomas are uncommon and varied, and patients are spread across specialist hematology and oncology centers rather than reachable through broad campaigns. Many learn about research only through advocacy organizations, treatment centers, and communities they already trust. Generic digital outreach and purchased lists do not close that gap. Relationships embedded in the Lymphoma community do.

In a T-Cell / Non-Hodgkin Lymphoma engagement, Leapcure reached 891 patients through 80+ Lymphoma advocacy partnerships and trusted community leaders, the channels broad campaigns cannot replicate.

Subtype and eligibility complexity create screen failures before enrollment begins

Peripheral T-cell lymphoma spans several subtypes that qualify for different protocols, diagnosis depends on specialist pathology, and treatment history matters. These criteria are specific enough that many interested patients fail screening unless recruitment surfaces candidates matched to the protocol before site referral. Passing unqualified patients to sites wastes coordinator time and inflates screen-fail rates.

Leapcure assesses protocol eligibility before any patient is referred to a site. Sites receive candidates who have been pre-assessed and educated on what participation involves.

Studies that ignore the patient experience start slow and lose patients

T-cell lymphoma is aggressive and the protocols are demanding, so patients drop out when a study is not built around their reality. A trial designed without patient insight starts slowly and retains poorly. Understanding what patients actually need, before recruitment, is what keeps enrollment moving.

Leapcure ran a 1,114-response Lymphoma Patient Insights survey and used it to make a T-Cell Lymphoma study more patient-centric, which sped up study startup and improved recruitment and retention.

Advocacy is the right strategy for Lymphoma, but execution requires real relationships

Sponsors running Lymphoma studies already know advocacy-led outreach outperforms generic digital campaigns. The hard part is a partner with genuine, trusted relationships in the Lymphoma community, not one that buys list access or runs one-off email blasts to advocacy members.

Leapcure's Lymphoma advocacy network spans 80+ partnerships, including Lymphoma Coalition, the Leukemia & Lymphoma Society, the T-Cell Leukemia Lymphoma Foundation, and Lymphoma Action, with trust built before any recruitment begins.

Three Channels and One Insight-Led Strategy for Your T-Cell Lymphoma Trial.

Every T-Cell Lymphoma study is different. Leapcure starts with patient insight, then deploys the right mix of Lymphoma advocacy, influencer and direct-to-patient outreach, and physician-based awareness, mapped to your protocol, your sites, your geographies, and your timeline.

1

Start with patient insight, then activate the right channels

Leapcure begins by learning what patients need, through surveys and interviews with advocacy leaders, then activates the channels that reach T-cell lymphoma patients: 80+ Lymphoma advocacy partnerships, influencer and direct-to-patient campaigns, and physician-based awareness across specialist centers. Channel mix is adapted to the protocol, site locations, and eligibility criteria of each program.

2

Engage and support patients through pre-screening

Every patient is engaged by Leapcure's team before being assigned to a site. We assess protocol eligibility, including subtype where relevant, and confirm patients understand what participation involves. Caregivers and family members are included where helpful. Sites conduct official screening; Leapcure ensures the patients who arrive are informed and prepared, not referrals that create coordinator work.

3

Optimize in real time based on site engagement

Channel performance and site contact rates are tracked continuously across regions. Advocacy, influencer and direct-to-patient, and physician-based awareness contributions are rebalanced based on referral quality, site intake capacity, and protocol progress, so effort follows what each program actually needs.

T-Cell / Non-Hodgkin Lymphoma Patient Engagement and Insight, Delivered Before Recruitment.

Challenge Context

Indication

T-Cell / Non-Hodgkin Lymphoma, with a peripheral T-cell lymphoma (PTCL) focus

Geography

US and EU, including the United Kingdom, Spain, and France

Challenge

A rare, dispersed, heterogeneous T-cell population; aggressive disease with short enrollment windows; an advocacy-dependent community; and a need to understand the patient experience well enough to design a study patients would join and stay in.

Approach deployed

Lymphoma Patient Insights survey (1,114 responses) plus interviews with patient advocacy leaders on experience, needs, and sentiment; 80+ targeted Lymphoma advocacy (PAG) campaigns; influencer and direct-to-patient awareness; and physician-based awareness.

Results & Metrics

Patient insight

1,114-response Lymphoma Patient Insights survey, plus advocacy-leader interviews on the experience, needs, and sentiment of Lymphoma patients.

Patients engaged

891 T-Cell Lymphoma patients engaged across the US and Europe.

Subtype and interest

60% of patients engaged had peripheral T-cell lymphoma; 78% of those patients were interested in a clinical trial.

Study impact

Patient-informed study design made the trial more patient-centric, sped up study startup, and increased patient recruitment and retention.

Diversity reach

Engaged broader, more diverse populations early through trusted advocacy leaders. Capability claim; specific demographic results vary by study.

Sponsor trust

Built awareness of and trust in the sponsor ahead of any recruitment effort.

Sponsor attribution

Leading Hematology-Oncology Sponsor, T-Cell / Non-Hodgkin Lymphoma

Four Channels. Built for T-Cell Lymphoma. Active Before Your Trial Opens.

Leapcure reaches T-Cell Lymphoma patients through Lymphoma advocacy outreach, influencer and direct-to-patient campaigns, and physician-based awareness, and a fourth channel competing vendors do not currently offer: AEO and AI-search visibility for your trial.

Lymphoma Advocacy Network

  • •80+ active Lymphoma advocacy partnerships, including Lymphoma Coalition, the Leukemia & Lymphoma Society, the T-Cell Leukemia Lymphoma Foundation, Lymphoma Action, CancerCare, Hematon, and France Lymphome Espoir, plus regional and community networks.
  • •Content co-developed with advocacy partners so research is presented as a trusted option, not an unsolicited pitch. Patients hear about trials from sources they already trust.
  • •Outreach designed to reach broader, more diverse patient populations early, through trusted advocacy leaders.

Influencer and Direct-to-Patient

  • •Trusted patient voices and direct-to-patient campaigns that meet T-cell lymphoma patients where they already spend time and seek information.
  • •Mapped to site capacity in real time so referrals are modulated and patient quality is maintained.
  • •A supporting channel that amplifies advocacy reach; advocacy drives the majority of qualified engagement.

Physician-Based Awareness

  • •Awareness across the hematology and oncology centers, specialist practices, and treatment networks where T-cell lymphoma patients are actually diagnosed and managed.
  • •Surfaces patient segments that broad advocacy and digital reach can miss, especially for rarer subtypes.
  • •Framed as clinical-community awareness, not cold physician referral.

AEO and AI-Search Visibility for Your Trial

  • •Patients increasingly ask AI assistants and AI search about Lymphoma trials. Leapcure makes a trial genuinely retrievable the way good content always has: clear, server-rendered information written the way patients ask, backed by first-party data, dated statistics, and cited sources.
  • •The durable advantage is presence in the sources AI engines cite most, advocacy organizations and ClinicalTrials.gov. Leapcure's 80+ advocacy partnerships and trial presence are that third-party footprint.
  • •We do not promise AI visibility through schema or markup tricks. Accurate, crawlable information plus trusted third-party presence is the asset, and it compounds over the life of your study.

Built on Trusted Relationships in the Lymphoma Community

Leapcure's Lymphoma advocacy partnerships are active, named, and co-developed, not list purchases.

Lymphoma Coalition

Global network of Lymphoma patient organizations; international credibility anchor.

Leukemia & Lymphoma Society

Leading US blood-cancer organization; broad patient reach and trust.

T-Cell Leukemia Lymphoma Foundation

T-cell-specific advocacy; directly relevant to PTCL populations.

Lymphoma Action

Established UK Lymphoma charity; support and community across the UK.

CancerCare

Patient support services across cancer types; complements Lymphoma-specific reach.

Living with T-Cell Lymphoma? A clinical trial may be an option.

If you are living with T-cell lymphoma or peripheral T-cell lymphoma, a clinical trial may give you access to investigational treatments that are not yet widely available. We know a lymphoma diagnosis can move fast and feel overwhelming, with a lot to take in about treatment and what comes next. Leapcure's team offers step-by-step support, and we include your family or caregivers wherever that helps.

See if a T-Cell Lymphoma trial may be right for you
Leapcure kangaroo mascot

Leapcure's T-Cell Lymphoma recruitment team has run a T-Cell / Non-Hodgkin Lymphoma engagement built on 80+ Lymphoma advocacy partnerships and a 1,114-response patient insight study, engaging 891 patients across the US and Europe and making the study more patient-centric. We deploy advocacy, influencer and direct-to-patient, physician-based awareness, and AEO channels adapted to your protocol, and we can mobilize within 48 hours of program launch.

Talk to our T-Cell Lymphoma team